Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug ...

Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...

You’ve heard of the popular glucagon-like peptide-1 (GLP-1) receptor agonist drug semaglutide (Ozempic, Wegovy) and GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound). Now there’s a new kid on the weight ...

TRANSCEND-T2D-1 trial findings indicate that retatrutide provides significant improvements in HbA1c and cardiovascular risk factors. Topline results were announced from a phase 3 trial evaluating ...

But while Ozempic is arguably the most recognizable drug in its class, it isn’t the only medication approved for weight management. Others include Wegovy and Saxenda, while newer drugs like ...

Retatrutide is an new drug that has shown promise in the treatment of obesity and type 2 diabetes. Retatrutide is a type of multi-receptor agonist that targets multiple hormonal pathways involved in ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Please provide your email address to receive an email when new articles are posted on . Adults with obesity and knee osteoarthritis had reductions in body weight and knee pain with retatrutide. More ...

Retatrutide, a triple agonist, achieved significant weight loss and pain reduction in the TRIUMPH-4 trial for obesity and knee osteoarthritis. The trial's highest dose led to an average weight loss of ...

Injectable peptides are generating a lot of buzz online. One of these is retatrutide, a drug that’s being described as the next big thing in weight loss. Some say it may be even more powerful than ...